Proteomics

Dataset Information

0

Isoginkgetin derivative IP2 enhances the adaptive immune response against tumor antigens


ABSTRACT: The success of cancer immunotherapy relies on the induction of an immunoprotective response targeting tumor antigens (TAs) presented on MHC-I molecules. We demonstrated that the splicing inhibitor isoginkgetin and its water-soluble and non-toxic derivative IP2 act at the production stage of the Pioneer Translation Products (PTPs). We showed that IP2 increases PTP-derived antigen presentation in cancer cells in vitro and impairs tumor growth in vivo. IP2 action is long-lasting and dependent on the CD8+ T cell response against TAs. We observed that the antigen repertoire displayed on MHC-I molecules at the surface of MCA205 fibrosarcoma is modified upon treatment with IP2. In particular, IP2 enhances the presentation of an exon-derived epitope from the tumor suppressor nischarin. The combination of IP2 with a peptide vaccine targeting the nischarin-derived epitope showed a synergistic antitumor effect. These findings identify the spliceosome as a druggable target for the development of epitope-based immunotherapies.

INSTRUMENT(S): Orbitrap Fusion

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Cell Culture

SUBMITTER: Julien Marcoux  

LAB HEAD: Julien Marcoux

PROVIDER: PXD023019 | Pride | 2021-03-02

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
1831004-F1.raw Raw
1831004-F10.raw Raw
1831004-F11.raw Raw
1831004-F12.raw Raw
1831004-F2.raw Raw
Items per page:
1 - 5 of 24

Similar Datasets

2023-01-03 | PXD024067 | Pride
2021-03-26 | PXD024400 | Pride
2021-11-11 | PXD028550 | Pride
2023-04-24 | PXD037843 | Pride
2018-03-14 | PXD006081 | Pride
2022-07-01 | GSE202358 | GEO
| PRJNA835703 | ENA
2020-08-06 | GSE140397 | GEO
2021-09-09 | PXD019866 | Pride
2019-05-20 | PXD013066 | Pride